167 related articles for article (PubMed ID: 29622656)
1. A phase I study of romidepsin and ifosfamide, carboplatin, etoposide for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma.
Strati P; Chihara D; Oki Y; Fayad LE; Fowler N; Nastoupil L; Romaguera JE; Samaniego F; Garg N; Feng L; Wesson ET; Ruben CE; Stafford MD; Nieto Y; Khouri IF; Hosing C; Horowitz SB; Kamble RT; Fanale MA
Haematologica; 2018 Sep; 103(9):e416-e418. PubMed ID: 29622656
[No Abstract] [Full Text] [Related]
2. Combination of brentuximab-vedotin and ifosfamide, carboplatin, etoposide in relapsed/refractory peripheral T-cell lymphoma.
Van de Wyngaert Z; Coppo P; Cervera P; Fabiani B; Lemonnier MP; Corre E; Marjanovic Z; Aoudjhane M; Mohty M; Duléry R
Eur J Haematol; 2021 Apr; 106(4):467-472. PubMed ID: 33320379
[TBL] [Abstract][Full Text] [Related]
3. DexaBEAM versus ICE salvage regimen prior to autologous transplantation for relapsed or refractory aggressive peripheral T cell lymphoma: a retrospective evaluation of parallel patient cohorts of one center.
Mikesch JH; Kuhlmann M; Demant A; Krug U; Thoennissen GB; Schmidt E; Kessler T; Schliemann C; Pohlen M; Mohr M; Evers G; Köhler G; Wessling J; Mesters R; Müller-Tidow C; Berdel WE; Thoennissen NH
Ann Hematol; 2013 Aug; 92(8):1041-8. PubMed ID: 23532626
[TBL] [Abstract][Full Text] [Related]
4. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.
Abali H; Urün Y; Oksüzoğlu B; Budakoğlu B; Yildirim N; Güler T; Ozet G; Zengin N
Cancer Invest; 2008 May; 26(4):401-6. PubMed ID: 18443961
[TBL] [Abstract][Full Text] [Related]
5. Feasibility and usefulness of high-dose chemotherapy (high-dose ifosfamide, carboplatin and etoposide) combined with peripheral blood stem cell transplantation for male germ cell tumor: a single-institute experience.
Hara I; Miyake H; Yamada Y; Yamanaka K; Furukawa J; Kumano M; Takenaka A; Fujisawa M
Anticancer Drugs; 2006 Oct; 17(9):1057-66. PubMed ID: 17001179
[TBL] [Abstract][Full Text] [Related]
6. Use of ifosfamide, carboplatin and etoposide in combination with brentuximab vedotin or romidepsin based on CD30 positivity in relapsed/refractory peripheral T-cell lymphoma.
Gentille C; Sarfraz H; Joshi J; Randhawa J; Shah S; Pingali SR
Cancer Rep (Hoboken); 2022 Jul; 5(7):e1581. PubMed ID: 35263030
[TBL] [Abstract][Full Text] [Related]
7. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
8. Salvage chemotherapy for relapsed and resistant lymphoma with a carboplatin containing schedule--EPIC.
Richardson DS; Tighe M; Cull G; Johnson SA; Phillips MJ
Hematol Oncol; 1994; 12(3):125-8. PubMed ID: 7959640
[TBL] [Abstract][Full Text] [Related]
9. High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study. The German Testicular Cancer Cooperative Study Group.
Siegert W; Beyer J; Strohscheer I; Baurmann H; Oettle H; Zingsem J; Zimmermann R; Bokemeyer C; Schmoll HJ; Huhn D
J Clin Oncol; 1994 Jun; 12(6):1223-31. PubMed ID: 7911158
[TBL] [Abstract][Full Text] [Related]
10. Durable Response in Relapsed Adolescent Peripheral T-cell Lymphoma: A Case Report and Review of the Literature.
Wedekind MF; Saraf A; Willen F; Audino AN
J Pediatr Hematol Oncol; 2022 Jan; 44(1):e278-e281. PubMed ID: 33769385
[TBL] [Abstract][Full Text] [Related]
11. High-dose chemotherapy with carboplatin, etoposide and ifosfamide followed by autologous stem cell rescue in patients with relapsed or refractory malignant lymphomas: a phase I/II study.
Kleiner S; Kirsch A; Schwaner I; Kingreen D; Schwella N; Huhn D; Siegert W
Bone Marrow Transplant; 1997 Dec; 20(11):953-9. PubMed ID: 9422474
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of bortezomib plus ICE (BICE) for the treatment of relapsed/refractory Hodgkin lymphoma.
Fanale M; Fayad L; Pro B; Samaniego F; Liboon MJ; Nunez C; Horowitz S; Anderlini P; Popat U; Ji Y; Kwak LW; Younes A
Br J Haematol; 2011 Jul; 154(2):284-6. PubMed ID: 21517809
[No Abstract] [Full Text] [Related]
13. Treatment response and overall outcome of patients with relapsed and refractory peripheral T-cell lymphoma compared to diffuse large B-cell lymphoma.
Puig N; Wang L; Seshadri T; al-Farsi K; Keating A; Crump M; Kuruvilla J
Leuk Lymphoma; 2013 Mar; 54(3):507-13. PubMed ID: 22897731
[TBL] [Abstract][Full Text] [Related]
14. High-dose ifosfamide/carboplatin/etoposide with autologous hematopoietic stem cell support: safety and future directions.
Elias AD; Ayash LJ; Wheeler C; Schwartz G; Tepler I; McCauley M; Mazanet R; Schnipper L; Frei E; Antman KH
Semin Oncol; 1994 Oct; 21(5 Suppl 12):83-5. PubMed ID: 7992072
[TBL] [Abstract][Full Text] [Related]
15. Romidepsin treatment for relapsed or refractory peripheral and cutaneous T-cell lymphoma: Real-life data from a national multicenter observational study.
Shimony S; Horowitz N; Ribakovsky E; Rozovski U; Avigdor A; Zloto K; Berger T; Avivi I; Perry C; Abadi U; Raanani P; Gafter-Gvili A; Gurion R
Hematol Oncol; 2019 Dec; 37(5):569-577. PubMed ID: 31674027
[TBL] [Abstract][Full Text] [Related]
16. Treatment of peripheral T cell lymphoma with an intensive protocol ACEP (adriamycin, cyclophosphamide, etoposide and prednisolone) and ifosfamide showing an important response and overall survival rates.
Salamoon M; Bachour M; Hussein T; Kenj M
Med Oncol; 2013 Jun; 30(2):554. PubMed ID: 23550277
[TBL] [Abstract][Full Text] [Related]
17. Ifosfamide, carboplatin, and etoposide in combination for induction and high-dose chemotherapy: focus on breast cancer and lymphoma.
Fields KK; Elfenbein GJ; Saleh RA; Zorsky PE; Janssen WE; Perkins JB; Saleh TG; Piazza JT; Kronish LE; Machak MC
Hematol Oncol; 1992; 10(1):61-74. PubMed ID: 1563705
[No Abstract] [Full Text] [Related]
18. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma.
Moskowitz CH; Bertino JR; Glassman JR; Hedrick EE; Hunte S; Coady-Lyons N; Agus DB; Goy A; Jurcic J; Noy A; O'Brien J; Portlock CS; Straus DS; Childs B; Frank R; Yahalom J; Filippa D; Louie D; Nimer SD; Zelenetz AD
J Clin Oncol; 1999 Dec; 17(12):3776-85. PubMed ID: 10577849
[TBL] [Abstract][Full Text] [Related]
19. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy.
Mappa S; Marturano E; Licata G; Frezzato M; Frungillo N; Ilariucci F; Stelitano C; Ferrari A; Sorarù M; Vianello F; Baldini L; Proserpio I; Foppoli M; Assanelli A; Reni M; Caligaris-Cappio F; Ferreri AJ
Hematol Oncol; 2013 Sep; 31(3):143-50. PubMed ID: 23161567
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in treatment of newly diagnosed pediatric solid tumors.
Marina NM; Rodman JH; Murry DJ; Shema SJ; Bowman LC; Jones DP; Furman W; Meyer WH; Pratt CB
J Natl Cancer Inst; 1994 Apr; 86(7):544-8. PubMed ID: 8133538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
